Ratings by Raymond James (Sean McCutcheon)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/22/2026 | Black Diamond Therapeutics | BDTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/8/2026 | Engene Holdings Inc. | ENGN | Downgrade | Outperform (Strong Buy) |
8.85 (1.75) |
-80.23% | Details | |
| 4/28/2026 | Compass Therapeutics | CMPX | Downgrade | Market Perform (Outperform) |
1.79 (2.02) |
12.85% | Details | |
| 4/27/2026 | Relay Therapeutics | RLAY | Maintain | Strong Buy (N/A) |
|
Details | ||
| 4/21/2026 | Legend Biotech Corp. | LEGN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/15/2026 | Bristol-Myers Squibb Co. | BMY | Maintain | Market Perform (N/A) |
|
Details | ||
| 4/13/2026 | Revolution | RVMD | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/16/2026 | Bristol-Myers Squibb Co. | BMY | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/10/2026 | Legend Biotech Corp. | LEGN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/9/2026 | Engene Holdings Inc. | ENGN | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/6/2026 | Legend Biotech Corp. | LEGN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/5/2026 | Compass Therapeutics | CMPX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/24/2026 | Galapagos NV | GLPG | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/24/2026 | Vir Biotechnology | VIR | Upgrade | Strong Buy (Outperform) |
7.43 (9.95) |
33.92% | Details | |
| 2/23/2026 | Legend Biotech Corp. | LEGN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/19/2026 | Ocular Therapeutix | OCUL | Maintain | Strong Buy (N/A) |
|
Details | ||
| 1/20/2026 | Legend Biotech Corp. | LEGN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/9/2026 | BridgeBio Oncology Therapeutics, In | BBOT | New Coverage | Outperform (N/A) |
13.30 (7.44) |
-44.06% | Details | |
| 1/6/2026 | Compass Therapeutics | CMPX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/19/2025 | Galapagos NV | GLPG | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/11/2025 | Engene Holdings Inc. | ENGN | Upgrade | Strong Buy (Outperform) |
6.01 (8.85) |
47.25% | Details | |
| 10/17/2025 | Revolution | RVMD | Maintain | Strong Buy (N/A) |
|
Details | ||
| 9/12/2025 | Revolution | RVMD | New Coverage | Strong Buy (N/A) |
46.24 (169.77) |
267.15% | Details | |
| 9/5/2025 | Regenxbio Inc. | RGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/11/2025 | Compass Therapeutics | CMPX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/7/2025 | Regenxbio Inc. | RGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/24/2025 | Galapagos NV | GLPG | Maintain | Market Perform (N/A) |
|
Details | ||
| 7/11/2025 | Janux Therapeutics | JANX | New Coverage | Outperform (N/A) |
25.61 (14.64) |
-42.83% | Details | |
| 7/1/2025 | Black Diamond Therapeutics | BDTX | New Coverage | Outperform (N/A) |
2.48 (1.86) |
-25% | Details | |
| 7/1/2025 | Compass Therapeutics | CMPX | New Coverage | Outperform (N/A) |
2.60 (1.79) |
-31.15% | Details | |
| 6/12/2025 | Engene Holdings Inc. | ENGN | Maintain | Outperform (N/A) |
|
Details | ||
| 6/5/2025 | Regenxbio Inc. | RGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/30/2025 | Regeneron Pharma | REGN | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/13/2025 | Galapagos NV | GLPG | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/13/2025 | Legend Biotech Corp. | LEGN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/24/2025 | Galapagos NV | GLPG | Maintain | Market Perform (N/A) |
|
Details | ||
| 4/21/2025 | Regeneron Pharma | REGN | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/19/2025 | Regenxbio Inc. | RGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/7/2025 | Regenxbio Inc. | RGNX | New Coverage | Outperform (N/A) |
8.43 (9.97) |
18.27% | Details | |
| 11/27/2024 | Engene Holdings Inc. | ENGN | New Coverage | Outperform (N/A) |
8.60 (6.01) |
-30.12% | Details | |
| 8/2/2024 | Galapagos NV | GLPG | Downgrade | Market Perform (Outperform) |
26.89 (27.73) |
3.12% | Details | |
| 3/13/2024 | Legend Biotech Corp. | LEGN | New Coverage | Outperform (N/A) |
65.19 (29.38) |
-54.93% | Details | |
| 3/1/2024 | Regeneron Pharma | REGN | New Coverage | Market Perform (N/A) |
966.09 (623.43) |
-35.47% | Details |
